Target concentrations of plasma oestradiol to protect against osteoporosis have now been published in at least one textbook 1 and are increasingly discussed by clinicians. A survey of the literature revealed that many reports do not give details of oestradiol assay methods, despite the fact that there is a wide range of biases. Plasma oestradiol measurements made after ingestion of equine oestrogen preparations are not valid, and for oral oestradiol and oestradiol valerate preparations a single untimed sample does not give a reliable estimate of the average exposure over 24 h. Oestradiol measurements in plasma from women using patch, gel or implant preparations could be useful provided that consideration is given to the time of sampling and to the assay method used, although target levels have not been established. Further studies are required in this area.
Introduction
A recent study of general practitioners in the Birmingham (UK) area examined the subjects discussed when women were counselled about the bene¢ts of hormone replacement therapy (HRT). In addition to relieving menopausal symptoms, the prevention of osteoporosis was discussed with 80% of patients. 2 Standardized doses of oestradiol have been recommended for HRT, e.g. 0¢625 mg/day conjugated equine oestrogens by mouth, 2 mg/day oestradiol by mouth or 0¢05 mg/day in a patch. 3 However, studies suggest that between 5 and 20% of women absorb exogenous oestrogens poorly, 4 and 10-fold di¡erences in bioavailability have been reported for both oral and transdermal preparations. 5 Thus, on standardized doses of oestrogens, some women will not reach adequate plasma oestradiol levels whilst others may achieve levels which are too high, resulting in side e¡ects. This suggests that oestrogen therapy should be customized as proposed by de Lignieres. 6 The gold standard for bone density measurements is the dual energy X-ray absorptiometry (DEXA) scan; however, as the changes in bone density following the introduction of HRT are relatively small compared with the coe¤cient of variation (CV) of the technique, this cannot be used to assess bone density for at least a year and perhaps longer. It has become apparent to the authors whilst attending a variety of clinical meetings that some clinicians use a target concentration of plasma oestradiol of 200^300 pmol/L when treating menopausal women with HRT to prevent osteoporosis. The publication of these target concentrations in at least one textbook 1 led us to look at the evidence for such a level. This article examines the variable bias in plasma oestradiol methods most commonly used in the UK, the pharmacokinetics of HRT preparations and the evidence supporting use of plasma oestradiol concentrations to prevent osteoporosis.
Variable bias in plasma oestradiol methods
Data from the study by Cook and Read 7 and from the UK National External Quality Assessment Scheme (UK NEQAS) show large di¡erences in bias in oestradiol assays, ranging from 724 ¢1 to +26¢7% relative to the UK NEQAS all-laboratory trimmed mean (ALTM, see Table 1 ). Bias di¡erences from target values (ALTM) are greatest for the lowest oestradiol values in some assays [Diagnostic Productions Corporation (Gwynedd), UK NEQAS data]. Clearly, a target level of oestradiol must take these assay di¡erences into account, yet most studies reported in the literature pay little attention to oestradiol assay methods.
Hormone replacement therapy preparations and pharmacokinetics
Before looking at the evidence to support a target level, we need to consider the type of HRT preparations available and their pharmacokinetic properties. This discussion will be limited to the oestrogenic component of HRT only. A number of di¡erent formulations of HRT are available ; these include oral preparations (either pure oestradiol or equine preparations), transdermal`patches', percutaneous gels or subcutaneous implants.
Oral oestradiol
Oral oestradiol is absorbed from the gastrointestinal tract and passes ¢rst through the portal circulation. This`¢rst-pass' through the liver can result in 60^90% of the drug being metabolized, mainly to oestrone and its conjugates. 5 There are at least six pharmacokinetic studies of oestradiol levels following ingestion of oestradiol (see Table 2 ). Four of these studies demonstrate that the mean peak levels of oestradiol following ingestion of 2 mg oestradiol show just over twofold di¡erences from 275 to 587 pmol/L observed at between 3 and 8 h post-dose. The di¡erence between peak and nadir levels of oestradiol was 1¢7^2¢9-fold. One study showed a much higher peak value at 5962 pmol/L at 40 min, with a di¡erence between peak and nadir levels of 7¢4-fold after 3 weeks' oestradiol administration. Oestradiol was measured in this latter study, without solvent extraction, using the double antibody radioimmunoassay (RIA) kit produced by DPC. Con£icting results were observed in two studies in which the pharmacokinetics of oral oestradiol was examined on day 1and at a later stage. Sipinen and coworkers found that oestradiol concentrations were signi¢cantly higher after 1month of therapy than during the ¢rst day of treatment, for a 0¢2 mg dose of oestradiol but not for a higher dose of 1¢0 mg/day. 10 Setnikar and co-workers 15 in their study of the 2¢0 mg tablet found mean oestradiol levels to be 160% higher after administration of the last compared with the ¢rst tablet. The di¡erence between peak and trough values was still large (ratio 10¢8 compared with 7¢4 for the ¢rst and last tablet, respectively) in the latter study with signi¢cant accumulation of oestradiol during the ¢rst 6 days. A steadystate was achieved after 7 days.
The large variability in the time of the peak oestradiol level means that a single untimed sample will give an unreliable estimate of the average exposure over the 24-h period and cannot be recommended. There was also considerable variation in trough levels and the ratio of peak-to-trough values (1¢8^7¢4) in the longer-term studies. Trough levels were shown to represent 53^61% of the 24-h mean in two longerterm studies in which the area under the curve was calculated, 12, 15 although peak oestradiol levels di¡ered by a factor of 10 in these two studies, suggesting an assay bias di¡erence.
Similar considerations apply to the measurement of oestradiol levels following oestradiol valerate administration (e.g. Climesse 2 , Climagest 2 , Cycloprognova 2 , Nuvelle 2 and Tridestra 2 ). Oestrone was the principal oestrogen produced in serum by these preparations, with a ratio of oestrone to oestradiol of 3¢3 16, 17 and a ratio of peak-to-trough oestradiol of 6¢4. 17
Equine oestrogens
The equine preparations such as Premarin 2 , Premique 2 and Prempak C 2 contain equine oestrogens in addition to oestradiol. For example, Premarin 2 contains less than 1% of 17b-oestradiol, its main components being oestrone sulphate (48%), equilin sulphate (26%), 17a-dihydroequilin sulphate (17%) and 17a-oestradiol sulphate (3%). 18 The extent to which these equine oestrogens are bioactive in humans has not been fully established; however individual components such as equilin sulphate and 17b-dihydroequilin have been shown to have potent oestrogenic e¡ects. 19 In addition, these equine oestrogens have been shown to be measured to a variable extent by a number of assays. 20
Transdermal patches
Percutaneous and subcutaneous methods of oestradiol administration avoid high hepatic vein concentrations and the subsequent conversion to oestrone. The oestradiol/oestrone ratio measured on these preparations is thus close to 1. There are currently two di¡erent types of patch, the reservoir system and the matrix system. The Estraderm 2 (Ciba-Geigy, Horsham, West Sussex, UK) reservoir patch has been available in the UK for a number of years but the Estraderm 2 (Ciba-Geigy) matrix patch was only introduced into the British National Formulary in September 1999. In only one study was the type of patch under study speci¢ed (see Table 3 ). In two studies the area under the serum oestradiol curve was calculated and there was no di¡erence in values during a 3-week period. 13, 15 Fluctuation in levels with marked peak and trough levels was apparent in all ¢ve of the longer-term studies after several patch applications. 12, 13, 15, 21, 23 The di¡erence between peak and trough levels varied from 1¢3 to 1¢7 in two studies using the twice weekly 0 ¢ 05 mg/day patch (see Table 3 ) 13,21 but was much higher (ratio 10 ¢ 0 after 19 days) in the study by Jarvinen et al. 24 In the latter study this ratio was achieved by both higher peak and lower trough oestradiol levels compared with the other two studies. In the 3-week study published by Powers and co-workers for women using the 0¢05 mg/day twice weekly Estraderm 2 patch, trough levels after the sixth patch application represented 71% of the average level achieved during use of six patches. 13 Measurements were only made at 24 h intervals despite earlier demonstration of a peak oestradiol level at 8 h. A more detailed study of a 0¢05 mg/day twice weekly patch was performed by Setnikar et al. 15 Samples were taken at 6, 12, 24, 48 and 96 h and trough levels of oestradiol were found to represent 79% of the mean level during patch application.
In comparison with the twice weekly transdermal oestradiol system, the once weekly oestradiol patches showed comparable mean serum levels during the 1week study and similar di¡erences between peak and trough values (1¢9^2¢4). Trough oestradiol concentrations over the 7 days represented 76% and 72% of the average serum value for the 0¢1 and 0¢5 mg patch, respectively. 23 In conclusion, whilst the published data for this delivery mode are not entirely consistent, measurement of trough levels appears to represent the best time for sampling, due to variation in the time of peak levels found in di¡erent studies. These values represent, for example, between 70^80% of the serum levels achieved during the life of the 0¢5 mg/day twice weekly patch. For other patch systems, di¡erent correction factors seem to apply (see Table 3 ). The di¡erence between peak and trough levels for the ¢ve longer-term studies (range 1¢3^2¢5) suggests that failure to allow for the time of sampling may result in misleading interruption of any oestradiol levels measured.
Percutaneous gel
Application of a hydro-alcoholic gel of oestradiol to the human skin results in rapid penetration of the stratum corneum. This ¢rst stage of penetration occurs within 10 min of application. The di¡usion of the steroid into the whole epidermis and vascular system is slower, with a delay of several hours. 25 There are at least ¢ve published studies in which the pharmacokinetics of Oestrogel 2 (Hoechst Marion Roussel, Uxbridge, Middlesex, UK) preparations have been examined. Jarvinen and co-workers 26 have demonstrated that peak oestradiol levels and the area under the curve are greatest for a smaller application area, 200 cm 2 , compared with 400 cm 2 and an area as large as possible, using Divigel 2 (Orion Pharmaceutica, Espoo, Finland) containing 0 ¢ 1% oestradiol delivering 1mg/day. The women studied by the French group led by de Lignieres used a large surface area for application (2000 cm 2 , personal communication), although in the UK the recommended application area is 750 cm 2 .
In all the studies looking at the pharmacokinetics of oestradiol-containing gels, signi¢cant peaks and troughs were observed in plasma oestradiol levels but, as with other modes of delivery, there was considerable variation in the timing of peak levels between the di¡erent studies (4^24 h for gels applied daily, see Table 4 ).
Scott and co-workers, 12 studying Oestrogel 2 , found that trough levels represented 88% of the mean 24-h oestradiol levels in women using1¢5 mg oestradiol. The area of application was not stated in this study but the ratio of peak-to-trough values was similar to the study of Simon et al. 21 in which Oestrogel 2 was applied to a 750 cm 2 area. With a ratio of peak-to-trough oestradiol of 1¢3 to 1¢4 for 1¢5 mg oestradiol per day and 1¢7 for a 3¢0-mg dose, in these two studies the time of sampling, in relation to gel application, is important in interpreting oestradiol levels. With the smallest dose tested (0¢5 mg), or application of 1¢0 mg/day oestradiol over an area as large as possible, peak levels were observed for a much shorter period of time. Trough levels approximated to the mean level achieved over a 24-h period. 26, 28 In the two studies reported by Jarvinen et al. 26, 28 peak oestradiol levels di¡ered by a factor of 2¢6, when women were treated with a 1¢0-mg dose of oestradiol. Oestradiol was measured by the same method (RIA by Sorin Biomedica, Saluggia, Italy) in both studies. The area of gel application was marked out on the skin with a pen in the earlier but not the latter study, and this may have resulted in some error. Using an application area of 2000 cm 2 , de Lignieres found that levels of oestradiol 12 h after administration of gel containing 1¢5 mg of oestradiol were equivalent to the 24-h average (personal communication).
Oestradiol implants
When implants are used, plasma levels of oestradiol reach a peak approximately 2 weeks after insertion of a 25 mg implant and then gradually decline. Trough levels will give a value of approximately 67% of the average level achieved during the 6-month period. 29
Plasma oestradiol measurements and prevention of osteoporosis
The prevention of osteoporosis by oral oestrogens, both oestradiol and equine oestrogens, has been demonstrated in a number of studies^for example those performed by Lindsay et al. 30 and Ettinger et al. 31 Equine oestrogens are themselves active and are measured to variable extents by current assays. We therefore decided to focus in this review on oestradiol-only preparations. The study of Ettinger and co-workers 31 included 64 women who were assigned to one of four groups (placebo, 0¢5 mg, 1¢0 mg or 2¢0 mg micronized oral oestradiol). Mean bone density, measured at two sites [spinal-trabecular (T12 through to L3) and radial bone mineral density], was increased compared with controls in all treatment groups. A continuous skeletal dose^response e¡ect was observed in the range 0¢5^2¢0 mg oestradiol. The data of Ettinger and co-workers 31 also revealed that three out of nine women using 2 mg/day oestradiol su¡ered a loss of spinal trabecular bone density, suggesting that some women may be poor absorbers, or poor compliers. Theoretically, oestradiol measurements could be used to identify these women if consensus target values could be established. Several studies have looked at the e¡ect of oral, transdermal or subcutaneous oestradiol preparations on bone density and have also included oestradiol measurements, but in no study has the time of sampling in relation to oestradiol administration been considered. Five of these publications are summarized in Table 5 . The study of Palacios et al. 32 included data on oral HRT (oestradiol only) but no information was given about the time of sampling in relation to the dose of oral oestrogens, nor were there any details about the method used to measure oestradiol.
The study published by de Lignieres 6 looked at 179 postmenopausal women using oestradiol gel. The study was conducted over an 18-month period and included women increases the number of women who will develop oestrogenic side e¡ects.Theyalso recognize the importance of identifying those women who are poor responders. Other authors have also advocated this approach 37,38 but have not considered the time of sampling in relation to oestradiol administration. De Lignieres demonstrated that only 5¢5% of women having mean plasma levels greater than 220 pmol/L were losing more than1% spinal bone mass per year and only 3 ¢ 5% were losing more than 2%. Twenty-eight per cent of women having mean plasma levels of less than 220 pmol/Lwere losing more than1% spinal bone mass and 42¢9% more than 2%. 6 Similar conclusions were reached when the patch was studied by Devogelaer et al., 36 although only mean levels of oestradiol were reported for each treatment group. Again, the oestradiol assay method was not reported in these studies.The study of Field and co-workers, 34 using oestradiol patches (see Table 5 ), suggested a similar cut-o¡ for plasma oestradiol based on bone density measurements. The lowest dosage of patch (0¢025 mg/day) produced a mean oestradiol level of 140 pmol/L and was associated with substantial bone loss. With a middosage patch (0¢05 mg/day) the mean oestradiol level observed was 227 pmol/L and bone loss was prevented at this dose. Optimal results were achieved with the patch delivering 0¢1mg oestradiol/day. Accretion of bone was observed at this highest dose when mean oestradiol levels of 400 pmol/L were observed (see Table 5 ).
In the studies in which oestradiol levels were reported for women using either a gel or patch preparation, the preservation of bone density was achieved at a di¡erent level of oestradiol. For example, the mean oestradiol levels in the studies of Palacios et al. 32 and Devogelaer et al. 36 were 145 pmol/L and 316 pmol/L, respectively; however, no information about when the samples were taken in relation to oestradiol administration was given. This di¡erence may also demonstrate the di¤culty of using a single cut-o¡ level when oestradiol is measured with di¡erent assay methods. Part of this di¡erence may also re£ect the reporting of mean values for each treatment group. For example, in the study of Wimalawansa, 33 a sub-group of women was identi¢ed with low levels of oestradiol (less than 220 pmol/ L) in whom bone loss was signi¢cant (see Table 5 ). The women studied by Palacios 32 and Devogelaer 36 applied the same dose of Oestrogel 2 , although the mean plasma levels of oestradiol reported show a two-fold di¡erence. This could be ascribed to di¡erent application procedures for the Oestrogel 2 ; interestingly, the study in which the lower mean oestradiol level was reported showed the greater e¡ect on lumbar bone density. This supports the conclusion that method bias in oestradiol measurements is a signi¢cant factor.
A recent study looked at the plasma oestradiol levels in a group of women using Kliofem 2 , 2 mg/day oral oestradiol (personal communication, Dr MJ Diver and Prof WD Fraser, Royal Liverpool University Hospital, Liverpool, UK). These data were then compared with bone density data; again, no consideration was given to the time of sampling in relation to the dose. These workers concluded that a cut-o¡ level of 200 pmol/ L, measured using the Bayer Immuno 1 analyser, predicted those women in whom bone density was preserved. Using UK NEQAS bias data for the most widely used serum oestradiol assays, an approximate estimate can be made of oestradiol concentrations for other methods which correspond to a Bayer Immuno 1 oestradiol concentration of 200 pmol/ L.With the DPC Immulite or Immulite 2000 analyser this is approximately 160 pmol/ L; with the Roche Elecys it is approximately 250 pmol/L (see Table 1 , UK NEQAS data).
A number of studies have now reported results suggesting that lower doses of oestrogens may be e¡ective in preventing osteoporosis, although a consensus has not emerged. The study of Evans and Davie 39 suggested that a transdermal patch delivering 0 ¢ 025 mg/day oestradiol was as e¡ective as a 0 ¢ 05mg/day oestradiol patch at preserving bone mineral density (BMD) at both lumbar spine and femoral neck. A similar number of non-responders were identi¢ed in each dose group (3¢9% at the lumbar spine and 10¢4% at the femoral neck).
A study by Weiss and co-workers 40 using transdermal oestradiol patches at 0¢025, 0¢05, 0¢06 and 0¢1mg/day also concluded that all doses of HRT e¡ectively prevented bone loss. However, the data clearly show that there were patients who continued to lose BMD at the lumbar spine and hip. The number of such patients was greatest in the 0¢025 mg/day treatment group [e.g. at the hip, 5/14 (35¢7%) in the 0¢025 mg/ day group versus 4/18 (22%), 3/20 (15%) and 5/21 (23¢8%) in the 0¢05, 0¢06 and 0¢1mg/day groups, respectively].
Genant and co-workers 41 used three doses of ester-i¢ed oestrogens at 0¢3, 0¢625 and 1¢25 mg/day and found that the mean BMD in each group was doserelated. The 0¢3-mg dose group demonstrated increases in all the body areas measured, in contrast to a placebo group, in which reductions were seen at all sites. The low-dose esteri¢ed oestrogen used in the trial has recently been approved for prevention of osteoporosis in the USA. However, it is recognized that because the mean increase in femoral neck BMD was small in the 0¢3 mg/day oestradiol group, a signi¢cant proportion of patients were likely to be losing bone, but possibly at a reduced rate. 42 A strategy which can identify these women in the early months of treatment is clearly desirable.
Ultralow doses of 17b-oestradiol 7¢5 mg/day have also been reported to increase bone density in the forearm, but whether this is the case at other sites has yet to be established. 43 Studd and co-workers 44 were the ¢rst to look at the relationship between plasma oestradiol and bone density in women, using 6-monthly implants of 75 mg oestradiol and 0¢1 mg testosterone. Bone density was measured at the lumbar vertebrae and neck of femur by dual-photon absorptiometry before therapy and after 1year of subcutaneous therapy. The method of measurement of oestradiol was not reported. Of the 23 patients studied, 22 showed an increase in bone density after 1year of therapy. All patients had a pre-implantation serum oestradiol concentration greater than 200 pmol/L at 1year and a correlation between oestradiol level and bone accretion was observed. There was no correlation between plasma testosterone level and the increase in bone density.
In a later study, by the same group, the oestradiol levels using three di¡erent doses of implant, 25, 50 and 75 mg, were reported. 45 This study also found a signi¢cant relation between plasma oestradiol levels and increases in bone density at the lumbar spine and proximal femur. They concluded that none of the women lost bone density at the clinically important sites of spine and femoral neck if their oestradiol levels were above 300 pmol/L. Oestradiol was reported to be measured by RIA.
Conclusion
There is a need for greater awareness of the limitations of oestradiol assay methods^in particular, the relative bias di¡erences of many assays widely used in the UK and the variability of bias in relation to the ALTM at low levels of oestradiol. In addition, the pharmacokinetics of di¡erent oestradiol preparations must be appreciated. Evidence in the literature for using a particular cut-o¡ value for plasma oestradiol, which is su¤cient to prevent osteoporosis, is compromised by:
. Lack of documentation of the oestradiol method used. . Di¡erences in bias between laboratory oestradiol assays. . Lack of reference to the timing of sampling in relation to patch change or gel application.
. The small number of women included in many studies (see Tables 2^5).
. In the case of patch studies, a failure to specify the type of patch studied. . For gel preparations, lack of standardization of gel application area.
Despite these limitations, the trend to use HRT preparations which deliver lower doses of oestradiol means that the clinical need for establishing a bone density response is greater than ever. Early measurement of oestradiol levels within the ¢rst few months of treatment has been proposed to ful¢l this need. However, there is a paucity of evidence to support the setting of target levels at present. Further studies are clearly required in this area.
